Skip to main content
SpringerLink
Log in

Will Abuse-Deterrent Formulations of Opioid Analgesics Be Successful in Achieving Their Purpose?

  • Current Opinion
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

During the last 2 decades, there has been a dramatic increase in the use of strong opioids for chronic non-cancer pain. This increase has been accompanied by a steep increase in abuse, misuse, and both fatal and non-fatal overdoses involving prescription opioids. The situation is already alarming in the US. Prescription opioid-related harm is a complex, multifactorial issue that requires a multifaceted solution. In this respect, formulations of opioid analgesics designed to resist or deter abuse may be a useful component of a comprehensive opioid risk minimization programme. Such formulations have or are being developed. Abuse-resistant opioids include those that use some kind of physical barrier to prevent tampering with the formulation. Abuse-deterrent opioids are not necessarily resistant to tampering, but contain substances that are designed to make the formulation less attractive to abusers. This article focuses on two products intended to deter abuse that were reviewed by the US Food and Drug Administration (FDA).

The first (Embeda®) consists of extended-release morphine with sequestered naltrexone, an opioid antagonist that is released if the tablet is compromised by chewing or crushing. Although Embeda® exhibited abusedeterrent features, its label warns that it can be abused in a manner similar to other opioid agonists. Furthermore, tampering with Embeda® will result in the release of naltrexone, which may precipitate withdrawal in opioidtolerant individuals. In March 2011, all dosage forms of Embeda® were recalled because the product failed to meet routine stability standards, and its return date to the market is currently unknown. The second product (Acurox®) was intended to be both tamper resistant and abuse deterrent. It consisted of an immediate-release oxycodone tablet with subtherapeutic niacin as an aversive agent and used a gel-forming ingredient designed to inhibit inhalation and prevent extraction of the drug for injection. The new drug application for Acurox® was rejected in 2010 by the FDA because of concerns about the potential abuse-deterrent benefits of niacin.

While acknowledging that no one formulation can be expected to deter all types of opioid-abusive behaviours and no product is likely to be abuse proof in the hands of clear and determined abusers, the reductions in abuse these new products would provide may be an incremental step towards safer prescription opioids.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Dhalla IA, Persaud N, Juurlink DN. Facing up to the prescription opioid crisis [published erratum appears in BMJ 2011; 343: d5729]. BMJ 2011; 343: d5142

  2. Grady D, Berkowitz SA, Katz MH. Opioids for chronic pain. Arch Intern Med 2011; 171 (16): 1426–7

    Article  PubMed  Google Scholar 

  3. Manchikanti L, Fellows B, Ailinani H, et al. Therapeutic use, abuse, and nonmedical use of opioids: a ten-year perspective. Pain Physician 2010; 13: 401–35

    PubMed  Google Scholar 

  4. Nicholson B. Responsible prescribing of opioids for the management of chronic pain. Drugs 2003; 63 (1): 17–32

    Article  PubMed  Google Scholar 

  5. Woodcock J. A difficult balance: pain management, drug safety, and the FDA. N Engl J Med 2009; 361 (22): 2105–7

    Article  PubMed  CAS  Google Scholar 

  6. Bannwarth B. Irrelevance of the WHO analgesic ladder for managing rheumatic pain. Joint Bone Spine 2010; 77 (1): 1–3

    Article  PubMed  CAS  Google Scholar 

  7. United Nations Office on Drugs and Crime. World drug report 2011 [online]. Available from URL: http://unodc.org/unodc/en/data-and-analysis/WDR-2011.html [Accessed 2012 Mar 30]

  8. Okie S. A flood of opioids, a rising tide of deaths [published erratum appears in N Engl J Med 2011; 364: 290]. N Engl J Med 2010; 363 (21): 1981–5

    Article  PubMed  CAS  Google Scholar 

  9. Dunn KM, Saunders KW, Rutter CM, et al. Opioid prescription for chronic pain and overdose: a cohort study. Ann Intern Med 2010; 152 (2): 85–92

    Article  PubMed  Google Scholar 

  10. Bohnert ASB, Valenstein M, Bair MJ, et al. Association between opioid prescribing patterns and opioid overdoserelated deaths. JAMA 2011; 305 (13): 1315–21

    Article  PubMed  CAS  Google Scholar 

  11. Hall AJ, Logan JE, Toblin RL, et al. Patterns of abuse among unintentional pharmaceutical overdose fatalities. JAMA 2008; 300 (22): 2613–20

    Article  PubMed  CAS  Google Scholar 

  12. Dhalla IA, Mamdani MM, Sivilotti MLA, et al. Prescribing of opioid analgesics and related mortality before and after the introduction of long-acting oxycodone. CMAJ 2009; 181 (12): 891–6

    Article  PubMed  Google Scholar 

  13. Katz NP, Adams EH, Chilcoat H, et al. Challenges in the development of prescription opioid abuse-deterrent formulations. Clin J Pain 2007; 23 (8): 648–60

    Article  PubMed  Google Scholar 

  14. Holmes D. Prescription drug addiction: the treatment challenge. Lancet 2012; 379: 17–8

    Article  PubMed  Google Scholar 

  15. Centers for Disease Control and Prevention (CDC). Vital signs: overdoses of prescription opioid pain relievers — United States, 1999–2008. MMWR Morb Mortal Wkly Rep 2011; 60 (43): 1487–92

    Google Scholar 

  16. Fishbain DA, Cole B, Lewis J, et al. What percentage of chronic non-malignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidencebased review. Pain Med 2008; 9 (4): 444–59

    Article  PubMed  Google Scholar 

  17. Fields HL. Should we be reluctant to prescribe opioids for chronic non-malignant pain. Pain 2007; 129: 233–4

    Article  PubMed  Google Scholar 

  18. Passik SD. Issues in long-term opioid therapy: unmet needs, risks, and solutions. Mayo Clin Proc 2009; 84 (7): 593–601

    PubMed  Google Scholar 

  19. Webster LR, Cochella S, Dasgupta N, et al. An analysis of the root causes for opioid-related overdose deaths in the United States. Pain Med 2011; 12 Suppl. 2: 26–35S

    Article  Google Scholar 

  20. Centers for Disease Control and Prevention (CDC). Emergency department visits involving nonmedical use of selected prescription drugs — United States, 2004–2008. MMWR Morb Mortal Wkly Rep 2010; 59 (23): 705–9

    Google Scholar 

  21. Kuehn BM. Scientists probe ways to curb opioid abuse without hindering pain treatment. JAMA 2007; 297 (18): 1965–7

    Article  PubMed  CAS  Google Scholar 

  22. Centers for Disease Control and Prevention (CDC). Community- based opioid overdose prevention programs providing naloxone — United States, 2010. MMWR Morb Mortal Wkly Rep 2012; 61 (6): 101–5

    Google Scholar 

  23. Gugelmann HM, Perrone J. Can prescription drug monitoring programs help limit opioid abuse?. JAMA 2011; 306 (20): 2258–9

    Article  PubMed  CAS  Google Scholar 

  24. Raffa RB, Pergolizzi Jr JV. Opioid formulations designed to resist/deter abuse. Drugs 2010; 70 (13): 1657–75

    Article  PubMed  CAS  Google Scholar 

  25. Webster LR, Bath B, Medve RA. Opioid formulations in development designed to curtail abuse: who is the target?. Expert Opin Invest Drugs 2009; 18 (3): 255–63

    Article  CAS  Google Scholar 

  26. Webster L, St Marie B, McCarberg B, et al. Current status and evolving role of abuse-deterrent opioids inmanaging patients with chronic pain. J Opioid Manag 2011; 7 (3): 235–45

    Article  PubMed  Google Scholar 

  27. Schneider JP, Matthews M, Jamison RN. Abuse-deterrent and tamper-resistant opioid formulations: what is their role in addressing prescription opioid abuse?. CNS Drugs 2010; 24 (10): 805–10

    Article  PubMed  CAS  Google Scholar 

  28. US Department of Health and Human Services. US Food and Drug Administration. OxyContin: questions and answers [online]. Available from URL: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm207196.htm#4 [Accessed 2012 Aug 1]

  29. Mastropietro DJ, Omidian H. Current approaches in tamper-resistant and abuse-deterrent formulations. Drug Dev Ind Pharm. Epub 2012 Apr 26

  30. Smith HS. Morphine sulfate and naltrexone hydrochloride extended release capsules for the management of chronic, moderate-to-severe pain, while reducing morphine-induced subjective effects upon tampering by crushing. Expert Opin Pharmacother 2011; 12 (7): 1111–25

    Article  PubMed  CAS  Google Scholar 

  31. Ruan X. Sustained-release morphine sulfate with sequestered naltrexone for moderate to severe pain: a new opioid analgesic formulation and beyond. Expert Opin Pharmacother 2011; 12 (7): 999–1001

    Article  PubMed  CAS  Google Scholar 

  32. US Department of Health and Human Services. US Food and Drug Administration. Label approved on 07/09/2012 for EMBEDA. FDAApplicationNo (NDA) 022321 [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022321s007lbl.pdf [Accessed 2012 Aug 2]

  33. Daniels SE, Spivey RJ, Singla S, et al. Efficacy and safety of oxycodone HCl/niacin tablets for the treatment of moderate-to-severe postoperative pain following bunionectomy surgery. Curr Med Res Opin 2011; 27 (3): 593–603

    Article  PubMed  CAS  Google Scholar 

  34. US Department of Health and Human Services. US Food and Drug Administration. Label approved on 06/17/2011 forOXECTA.FDA Application No (NDA) 202080 [online]. Available from URL: http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/202080s000lbl.pdf [Accessed 2012 Aug 1]

  35. Cicero TJ, Ellis MS, Surratt HL. Effect of abuse-deterrent formulation of OxyContin. N Engl J Med 2012; 367 (2): 187–9

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

No sources of funding were used to conduct this study or prepare this manuscript. The author has no conflicts of interest that are directly relevant to the content of this article.

Author information

Authors and Affiliations

  1. Department of Rheumatology, Pellegrin Teaching Hospital, and Division of Therapeutics, Bordeaux Segalen University, Bordeaux, France

    Bernard Bannwarth

Authors
  1. Bernard Bannwarth
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bernard Bannwarth.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bannwarth, B. Will Abuse-Deterrent Formulations of Opioid Analgesics Be Successful in Achieving Their Purpose?. Drugs 72, 1713–1723 (2012). https://doi.org/10.2165/11635860-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/11635860-000000000-00000

Keywords

Search

Navigation